CELECOXIB 200 MG — DIN 02413027
CELECOXIB : 200 MG · ALEMBIC PHARMACEUTICALS LIMITED · CAPSULE · wholesale supply in Canada
Health Canada status: APPROVED
What is CELECOXIB?
CELECOXIB 200 MG contains CELECOXIB : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02413027, held by ALEMBIC PHARMACEUTICALS LIMITED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as approved, status dated 24-Nov-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is CELECOXIB used for?
Relief of symptoms of Osteoarthritis, Adult Rheumatoid Arthritis, and Ankylosing Spondylitis; short-term (≤ 7 days) management of moderate to severe acute pain in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Celecoxib cost around the world?
Celecoxib is listed on 17 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 4 | 102 | USD███.██ |
| Saudi Arabia | public | 27 | 48 | SAR███.██ |
| Spain | PVP con IVA (public price) | 27 | 34 | EUR███.██ |
| South Africa | single exit price | 31 | 32 | ZAR███.██ |
| Bahrain | retail (max) | 16 | 25 | BHD███.██ |
| Sweden | AIP (pharmacy purchase price) | 6 | 24 | SEK███.██ |
| United Arab Emirates | public | 13 | 23 | AED███.██ |
| Italy | prezzo al pubblico (classe A) | 6 | 17 | EUR███.██ |
| Australia | ex-manufacturer | 8 | 16 | AUD███.██ |
| Romania | max producer price | 12 | 13 | RON███.██ |
| Luxembourg | reimbursement | 9 | 9 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 2 | 8 | CZK███.██ |
| Morocco | PPV (public price) | 3 | 5 | MAD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 2 | 4 | EUR███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| Hungary | producer price (ex-factory) | 1 | 1 | HUF███.██ |
365 pack listings across 171 brand entries and 15 price bases, refreshed 08 Sep 2026. Ranges span every Celecoxib pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Celecoxib in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
27 holders have a Canadian DIN containing Celecoxib, across 69 DINs, of which 30 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| LABORATOIRE RIVA INC. | 6 | 2 | CELECOXIB, RIVA-CELECOX, RIVA-CELECOXIB | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 4 | 2 | IPG-CELECOXIB, MAR-CELECOXIB | Sourceable in Canada |
| NORA PHARMA INC | 4 | 2 | NRA-CELECOXIB, PRIVA-CELECOXIB | Sourceable in Canada |
| PHARMASCIENCE INC | 4 | 2 | PMS-CELECOXIB, PMSC-CELECOXIB | Sourceable in Canada |
| ANGITA PHARMA INC. | 2 | 2 | AG-CELECOXIB | Sourceable in Canada |
| APOTEX INC | 2 | 2 | APO-CELECOXIB | Sourceable in Canada |
| AURO PHARMA INC | 2 | 2 | AURO-CELECOXIB | Sourceable in Canada |
| BGP PHARMA ULC | 2 | 2 | CELEBREX | Sourceable in Canada |
| BIOMED PHARMA | 2 | 2 | BIO-CELECOXIB | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 2 | JAMP-CELECOXIB | Sourceable in Canada |
| MANTRA PHARMA INC | 2 | 2 | M-CELECOXIB | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 2 | 2 | MINT-CELECOXIB | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 200 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 30, 100, 500, 1000 and unit dose cartons of 100 capsules (10 blisters x 10 capsules). |
| Storage | Not explicitly stated in provided text (section 11 header present but content cut off). Typical storage is 15-30°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Celecoxib |
|---|---|
| ATC code | M01AH01 |
| AHFS class | 28:08.04.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02413027 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2413027 |
| Brand name | CELECOXIB |
| Generic / active ingredient | CELECOXIB : 200 MG |
| Market authorization holder | ALEMBIC PHARMACEUTICALS LIMITED |
| Health Canada schedule | Prescription |
| ATC code | M01AH01 |
| ATC anatomical main group | M — Musculo-skeletal system |
| ATC therapeutic subgroup | M01AH |
| Current status | APPROVED |
| Status date | 24-Nov-2014 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
OA: 200 mg/day; RA: 100-200 mg BID; Ankylosing Spondylitis: 200 mg/day; Acute Pain: 400 mg day 1, then 200 mg daily (max 7 days). Use lowest effective dose for shortest duration.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
CABG surgery setting; third trimester pregnancy; breastfeeding; severe heart failure; hypersensitivity to celecoxib or sulfonamides; history of asthma/allergic reactions to ASA or NSAIDs; active GI bleed.
Warnings and precautions
Increased risk of serious cardiovascular thrombotic events (MI, stroke); risk of serious GI events (bleeding, ulceration); potential for fluid retention, edema, and hypertension.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
30 of 69 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-CELECOXIB | 200 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | 02437589 |
| AG-CELECOXIB | 100 MG | CAPSULE | ANGITA PHARMA INC. | MARKETED | 02437570 |
| APO-CELECOXIB | 200 MG | CAPSULE | APOTEX INC | MARKETED | 02418940 |
| APO-CELECOXIB | 100 MG | CAPSULE | APOTEX INC | MARKETED | 02418932 |
| AURO-CELECOXIB | 100 MG | CAPSULE | AURO PHARMA INC | MARKETED | 02445670 |
| AURO-CELECOXIB | 200 MG | CAPSULE | AURO PHARMA INC | MARKETED | 02445689 |
| BIO-CELECOXIB | 200 MG | CAPSULE | BIOMED PHARMA | MARKETED | 02426390 |
| BIO-CELECOXIB | 100 MG | CAPSULE | BIOMED PHARMA | MARKETED | 02426382 |
| CELEBREX | 100 MG | CAPSULE | BGP PHARMA ULC | MARKETED | 02239941 |
| CELEBREX | 200 MG | CAPSULE | BGP PHARMA ULC | MARKETED | 02239942 |
2 · Same class — other molecules in ATC M01AH
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Celecoxib | ACCEL-CELECOXIB · ACT CELECOXIB · AG-CELECOXIB · APO-CELECOXIB · +25 more | 69 | 30 | Yes |
| Rofecoxib | VIOXX SUSPENSION 12.5MG/5ML · VIOXX TAB 12.5MG · VIOXX TAB 25MG | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC M01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| M01AE | Fenoprofen · Flurbiprofen · Ibuprofen · Ibuprofen, Combinations · Ketoprofen · +5 more | 398 | 101 |
| M01AB | Diclofenac · Diclofenac, Combinations · Etodolac · Indometacin · Ketorolac · +2 more | 170 | 38 |
| M01AC | Meloxicam · Piroxicam · Tenoxicam | 67 | 14 |
| M01AG | Mefenamic Acid | 7 | 1 |
| M01AX | Nabumetone | 12 | 1 |
| M01AA | Oxyphenbutazone · Phenylbutazone · Phenylbutazone, Combinations | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CELECOXIB called?
The same molecule, Celecoxib, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Celebrex | Latin | Australia, Bahrain, Czechia, Morocco, Saudi Arabia |
| Gloxib | Latin | Bahrain, Saudi Arabia |
| Celebra® | Latin | Sweden |
| Celecoxib Accord | Latin | Sweden |
| Celecoxib Medical Valley | Latin | Sweden |
| ACLEXA | Latin | Czechia |
| Celecoxib Krka | Latin | Sweden |
| Celecoxib STADA | Latin | Sweden |
| Celecoxib Sandoz | Latin | Australia, Sweden |
| COXICEL | Latin | Bahrain |
| JOSWE FLAMEX | Latin | Bahrain |
| PEDEXA | Latin | Bahrain, Saudi Arabia |
| APX-Celecoxib | Latin | Australia |
| Blooms Celecoxib | Latin | Australia |
| Cebatix | Latin | Bahrain, Saudi Arabia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.